¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑÆó¾ÏÇÐȸ (ÇÏÀ̺긮µå)2022 KALC International Conference-1ÀÏÂ÷ : 2022-11-10

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇÑÆó¾ÏÇÐȸ (ÇÏÀ̺긮µå)2022 KALC International Conference-1ÀÏÂ÷ : 2022-11-10
±³À°ÀÏÀÚ : 2022-11-10
±³À°Àå¼Ò : ·Ôµ¥È£ÅÚ¿ùµå Å©¸®½ºÅ»·ë(ÇÏÀ̺긮µå Çмú´ëȸ)  
±³À°ÁÖÁ¦ : (ÇÏÀ̺긮µå)2022 KALC International Conference-1ÀÏÂ÷
ÁÖÃÖ±â°ü : ´ëÇÑÆó¾ÏÇÐȸ
´ã´çÀÚ : ±èÀÎÁ¤
¿¬¶ôó : 02-741-8540  
À̸ÞÀÏ : kalc@lungca.or.kr      
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ÈäºÎ¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, °áÇÙ°ú, º´¸®°ú, ÇÙÀÇÇаú      
Âü¼®¿¹»óÀοø : 600¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 8 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 110,000¿ø      
ºñ°í       

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 07:50~08:40 Overcoming Resistance after 3rd Generation TKI Treatment in EGFR Mutant Non-Small Cell Lung Cancer  Suresh S. Ramalingam(Emory Univ., USA) 
È޽Ġ11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 08:40~08:50 È޽Ġ () 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 08:50~09:10 Extent of Lymph Node Dissection during Sublobar Resection  Yoohwa Hwang(Seoul National Univ) 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 09:10~09:30 Sublobar Resection in Compromized Patients  Jeong Su Cho(Sungkyunkwan Univ.) 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 09:30~09:50 Additional Management (for Incomplete or Local Recurrence) after Sublobar Resection  Seong Yong Park(Sungkyunkwan Univ.) 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 09:50~10:10 Japan Clinical Oncology Group Studies about Sublobar Resection  Hisashi Saji(St. Marianna Univ., Japan) 
È޽Ġ11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 10:10~10:30 È޽Ġ () 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 10:30~11:00 Antibody-Drug Conjugates: A Promising Novel Therapeutic Approach in Lung Cancer  David Planchard(Gustave Roussy, France) 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 11:00~11:20 EGFR-TK Degradation by PROTACs  Sumi Lee(J2HBiotech) 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 11:20~11:50 LAG 3 Immunotherapy in Lung Cancer  Scott Nicholas Gettinger(Yale Univ. Medical Center, USA) 
È޽Ġ11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 11:50~12:00 È޽Ġ () 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 12:00~12:40 Spotlighting the New 3rd generation EGFR TKI, Lazertinib: Updated Clinical Study Results & Real World Outcomes  Sun Min Lim(Yonsei Univ) 
È޽Ġ11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 12:40~13:00 È޽Ġ () 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 13:00~13:30 Expanding the Benefits of Immunotherapy for Cancer: Combine and Conquer  Dan G. Duda(Harvard Medical School, USA) 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 13:30~14:05 Atezolizumab-Grab: Beyond the PD-L1 Blockade in Cancers  Keehoon Jung(Seoul National Univ) 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 14:05~14:40 Combination of Two Distinct Subsets of Peripheral Blood CD8+ T Cells from Patients with Non-Small Cell Lung Cancer Predicts Response Outcome to Immune Checkpoint Blockade Therapy  Jae Ho Cho(Chonnam National Univ.) 
È޽Ġ11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 14:40~15:00 È޽Ġ () 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 15:00~15:30 Chest Imaging of Treatment-Related Pneumonitis  Hyae Young Kim(National Cancer Center) 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 15:30~16:00 How to Deal with Treatment-Related Pneumonitis  Sun Min Lim(Yonsei Univ.) 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 16:00~16:40 Optimal Management of Radiation and Drug Related Pneumonitis in Unresectable Stage III Non-Small Cell Lung Cancer Patients  William N. William(UT MD Anderson Cancer Center, USA) 
È޽Ġ11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 16:40~16:50 È޽Ġ () 
±³À°½Ã°£ 11-10 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 16:50~17:40 Pembrolizumab Combination Strategies in Lung Cancer: Present and Future  Bin Zhao(MSD Global Clinical Research) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑÆó¾ÏÇÐȸ (ÇÏÀ̺긮µå)2022 KALC International Conference-1ÀÏÂ÷ : 2022-11-10""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2022³â ´ëÇÑ°ñ´ë»çÇÐȸ Á¦34Â÷ Ãß°èÇмú´ëȸ(1ÀÏÂ÷) : 2022-11-11
´ÙÀ½±Û °æ»ó±¹¸³´ëÇб³º´¿ø ¼­ºÎ°æ³² À̺ñÀÎÈÄ°ú Áý´ãȸ ¿¬¼ö±³À°(³»½Ã°æ ±Í¼ö¼úÀÇ ½Ç·Ê) : 2022-11-09
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20790 °æ±â ´ëÇÑÇǺΰúÇÐȸ Á¦52Â÷ ÀÎõºÎõÁöºÎȸ ÇмúÁý´ãȸ : 2024-06-15 0 3 2024-05-27
20789 ¼­¿ï 2024³â ´ëÇѽŰæ±ÙÀ°ÁúȯÇÐȸ ¿¬¼ö°­Á : 2024-06-15 0 6 2024-05-27
20788 Á¦ÁÖ ´ëÇѳ»ºÐºñÇÐȸ Á¦22ȸ ºÐ°úÀü¹®ÀÇ ¿¬¼ö°­Á : 2024-06-15 0 4 2024-05-27
20787 Ãæ³² (¿Â¶óÀÎ)2024³âµµ Ãæû³²µµÀÇ»çȸ Ãá°èÇмú´ëȸ : 2024-06-15 0 5 2024-05-27
20786 ºÎ»ê KSMO ºÎ»ê¿ï»ê°æ³²/´ë±¸°æºÏÁöȸ °øµ¿ ½ÉÆ÷Áö¾ö : 2024-06-14 0 4 2024-05-27
20785 ¼­¿ï 2024³â ´ëÇѺҾÈÀÇÇÐȸ Ãá°èÇмú´ëȸ (´Ù½Ã, °Ü¿ï³ª¹«¿¡¼­ º½ ³ª¹«¿¡·Î From Traditional approaches to Innovation in Psychiatry) : 2024-06-14 0 7 2024-05-27
20784 ¼­¿ï ´ëÇÑ°áÇÙÇùȸ 2024³â °áÇÙ°ü¸®±³À° 1±â(2ÀÏÂ÷) : 2024-06-14 0 4 2024-05-27
20783 ¼­¿ï Á¦14Â÷ Çѱ¹ÃÖ¼Òħ½ÀÃéÀå¼ö¼ú¿¬±¸È¸ : 2024-06-14 0 3 2024-05-27
20782 ´ëÀü 2024 Á¦40ȸ ´ëÇѼҾƿܰúÇÐȸ Ãá°èÇмú´ëȸ ¹× 40Áֳ⠱â³äÇà»ç (2ÀÏÂ÷) : 2024-06-14 0 5 2024-05-27
20781 ´ë±¸ Ä¥°î°æºÏ´ëÇб³º´¿ø RARE DISEASE SYMPOSIUM 2024 : 2024-06-14 0 2 2024-05-27
20780 ºÎ»ê 2024 ´ëÇѽŰæ¿Ü°úÇÐȸ ºÎ»ê¿ï»ê°æ³²Áöȸ Á¦2Â÷ Á¤±âÇмú´ëȸ : 2024-06-14 0 5 2024-05-27
20779 ¼­¿ï 2024 ´ëÇÑÀÇÇÐȸ Çмú´ëȸ : 2024-06-14 0 5 2024-05-27
20778 ¼­¿ï ´ëÇÑÁø´ÜÀ¯ÀüÇÐȸ 2024³â Á¦19Â÷ Çмú´ëȸ (2ÀÏÂ÷) : 2024-06-14 0 7 2024-05-27
20777 ¼­¿ï 2024 ´ëÇÑÈ­»óÇÐȸ Çмú´ëȸ(2ÀÏÂ÷) : 2024-06-14 0 5 2024-05-27
20776 ºÎ»ê 2024³â Çѱ¹°£´ãÃé¿Ü°úÇÐȸ ºÎ¿ï°æÁöȸ °£ÀÌ½Ä ½ÉÆ÷Áö¾ö : 2024-06-14 0 5 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷